drugset / Trial / NCT07681674

Bicycle Continued Access Protocol (BiCAP) for Participants Receiving a Bicycle Investigational Product

NCT07681674

Phase 2 Not yet recruiting 16 enrolled BicycleTx Limited
Non-randomizedSingle-groupOpen-labelTreatment

Summary

BiCAP-201 trial offers continued access to Bicycle investigational product treatments zelenectide pevedotin, nuzefatide pevedotin, and BT7480 for participants currently receiving and deriving clinical benefit from one of these treatments in a Bicycle Therapeutics-sponsored clinical trial. Bicycle Therapeutics will continue to monitor longer term safety of these treatments.

Timeline

Start
2026-08-01
Primary completion
2030-05-30
Completion
2030-05-30

Drugs

EvaluationDrugModalityDoseRoute
Subject BT5528 Other / unclassified
Subject BT7480 Peptide
Subject Zelenectide pevedotin Protein / enzyme biologic

Indications